作者: Jonathan Whisenant , Emily Bergstand
DOI: 10.1007/S11864-005-0044-8
关键词: Tumor progression 、 Vascular endothelial growth factor 、 Medicine 、 Neuroendocrine tumors 、 Angiogenesis 、 Anti angiogenic 、 Disease 、 Colorectal cancer 、 Bevacizumab 、 Oncology 、 Internal medicine
摘要: Advances in our understanding of the mechanisms underlying tumor progression suggest that angiogenesis plays a key role gastrointestinal malignancies. Vascular endothelial growth factor (VEGF) has emerged as an important therapeutic target, and variety strategies to inhibit VEGF are under investigation. The approval bevacizumab for use patients with previously untreated metastatic colorectal cancer was based on clinical data suggesting is valid target this disease. As mature from ongoing trials, inhibitors treatment colon other malignancies will be more clearly defined. Additional information needed identify diseases stages most likely benefit anti-angiogenic agents optimal sequences combinations should studied.